A national survey of tuberculosis after hematopoietic stem cell transplant (SCT) was undertaken to study incidence, clinical presentation and outcome. Twenty confirmed cases were found among 8013 patients (eight in 5147 autologous and 12 in 2866 allogeneic SCT). The estimated incidence in cases/10 5 patients/year (95% CI) was 101 (56.5-145) for the whole group, 71.1 (21.8-120) in autologous and 135.6 (58.9-212) in allogeneic transplants. Compared with the general population, tuberculosis was more frequent after allogeneic (RR 2.95) but not after autologous SCT. Tuberculosis after SCT is a late infection (median 324 days post transplant), predominately affects the lungs (80% of the cases), appears to respond well to treatment but has a high mortality (25%) in allogeneic recipients. It can also complicate the post-transplant management as antituberculosis drugs frequently decrease the serum levels of cyclosporine causing an aggravation of GVHD. Graft-versus-host disease, corticosteroid treatment and total body irradiation appear to be associated with tuberculosis in allogeneic recipients. No obvious factors were associated with tuberculosis in autologous transplants. Finally, we found that the published literature on tuberculosis after solid and SCT has overestimated its incidence due to the direct translation of tuberculosis frequency into incidence. Bone Marrow Transplantation (2000) 26, 291-298.
immunodeficiencies that these patients suffer. However, in spite of the worldwide epidemic, 1 tuberculosis has been rarely described in recipients of SCT with only 33 cases reported to date. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Nonetheless the incidence of tuberculosis after SCT has been estimated to be 10-40 times higher than in the general population. 9, 10 A similarly high estimated incidence of tuberculosis has been found in solid organ transplants, where tuberculosis has been much better studied than in SCT with more than 270 cases reported. 14 However, previous publications have, in reality, estimated the relative frequency of this infection rather than its incidence.
Spain has a high incidence of tuberculosis (40-45 cases/10 5 inhabitants/year) and a high prevalence of infection (25-29%) that increases to 56% in people у49 years old, 15, 16 the highest incidence of tuberculosis in Europe after Portugal. 17 It also has one of the highest transplant activities in Europe. 18 Thus, due to the combination of these two facts, it would be reasonable to expect a substantial number of cases of post-SCT tuberculosis in Spanish patients. This fact, together with the scarce information about this infection in SCT, encouraged us to perform a national survey of post-transplant tuberculosis with two objectives: to assess the clinical presentation and outcome of post-SCT tuberculosis, and to estimate its incidence, comparing it with the incidence in the general Spanish population.
Patients and methods

Survey
In October 1997, a questionnaire was sent to all Spanish centers that performed SCT in 1996. Centers were asked to report retrospectively all diagnosed cases of tuberculosis post-SCT and the number of transplants performed by year.
Case definition
Only patients with post-transplant tuberculosis were included. The diagnosis of tuberculosis was considered certain if Mycobacterium tuberculosis was cultured from a clinical sample, and probable when acid-fast bacilli were seen (with or without caseating granulomata on histopathology) in patients with a clinical picture suggestive of tuberculosis. Tuberculosis was classified as pulmonary, extrapulmonary or disseminated according to the Working Group recommendations. 19 
Incidence of tuberculosis in the general Spanish population
A recent national survey of tuberculosis disclosed a global incidence of 38 cases/10 5 inhabitants/year, and for the HIV negative general population it was 31 cases/10 5 . 20 The rate of 38 cases/10 5 inhabitants/year was chosen in our study as the reference value for the general Spanish population. This incidence is higher than the official incidence which was (cases/10 5 inhabitants/year) 22.3 in 1995, 17 21 .2 in 1996 and 22.03 in 1997 (unpublished data from the National Epidemiologic Center, Instituto de Salud Carlos III). International organizations and national experts generally accept that the official incidence figures represent a substantial underreporting.
1,16
Search of the literature
The English language literature on tuberculosis and SCT was reviewed using MEDLINE. Cases were excluded if tuberculosis was diagnosed before transplantation or if there was no microbiologic (culture or microscopic) confirmation of the diagnosis. Publications which did not give microbiologic details, but considered the case as tuberculosis were accepted.
Statistical analysis
We estimated the incidence of tuberculosis in the transplant population by dividing the number of patients diagnosed with tuberculosis by the amount of population-time accrued by the observed transplant population, expressed in person × 10 −5 /year. As we do not have the individual survival time for the 8013 transplant patients, the amount of population-time accrued was estimated by three negative exponential equations. We assumed that allogeneic patients had a 20% mortality by day +100 and a plateau survival of 40% at 4 years, and autologous recipients a 10% mortality by day +100 and the same survival at 4 years (40%). For the whole group, a 15% mortality by day +100 and a 40% plateau survival at 4 years was assumed. These survival and mortality figures are conservative estimations for a group of patients with several diseases and statuses at transplant. [21] [22] [23] [24] [25] Equations for the calculation of populationtime accrued were for allogeneic patients f(x) = 0.60 × e + 0.4. The estimated incidence of tuberculosis, with a 95% CI, was compared with the incidence in the general Spanish population (38 cases/10 5 inhabitants/year) and considered statistically different if the incidence in the general Spanish population was outside the 95% CI of the transplant incidence. We compared allogeneic and autologous data by chisquare or Mann-Whitney, as appropriate. A significance level of 0.05 was used for all analyses. The calculation of amount of population-time accrued and tuberculosis incidence in transplant patients was done with the program Mathematica v2.0 (Wolfram Research Inc, Champaign, IL, USA). The program CIA v1.2 (MJ Gardner, British Medical Journal Publishing Group, London, UK) was used for 95% CI incidence calculations.
Results
During the period 1976-1998 a total of 8013 transplants (5147 autologous, 2866 allogeneic) were reported by 21 centers. Twenty-five cases were reported of which 20 met the criteria for post-transplant tuberculosis (19 certain, one probable) and five cases were excluded (one with pretransplant tuberculosis; one atypical mycobacterium; three patients without microbiologic or histopathologic confirmation of the clinically suspected tuberculosis). Two cases (L11 and L12) have been reported previously. 7 The median follow-up of the patients with tuberculosis was 1100 days (range, 211-2240).
Clinical features of the patients with tuberculosis (Tables 1 and 2)
There were nine males and 11 females, with a median age of 37 years (range, 19-57). Twelve patients received a transplant from an HLA-identical sibling (only one patient, L12, received a T cell-depleted allograft) and eight were autologous transplants. One patient (L8) had a history of pretransplant tuberculosis, and two cases (L2, A8) had an abnormal pretransplant chest X-ray related to non-tuberculosis causes. Only one patient (L8) received chemoprophylaxis with isoniazid after transplant. PPD skin testing was performed pretransplant only in three out of 20 patients, and gave a negative result in all. No delayed-type hypersensitivity skin testing was carried out in these patients to exclude an anergic state. In five patients PPD skin testing was performed at the time of tuberculosis presentation and was positive in only one case (L1). The majority of allogeneic patients with post-transplant tuberculosis suffered graft-versus-host disease (GVHD), received corticosteroids and were conditioned with total body irradiation (TBI). No obvious predisposing factors were found in autologous patients. Autologous patients had several significant differences compared with allogeneic patients (Table 2) : sex distribution (more females), underlying disease (more lymphomas than leukemias), conditioning regimens (less TBI), source of stem cells (more peripheral blood than bone marrow) and use of post-transplant corticosteroids prior to tuberculosis (none in autologous vs 92% in allogeneic).
All allogeneic (except case L8) and none of the autologous patients received post-transplant corticosteroids prior to the development of tuberculosis, for a median of 114 days (range, 14-365). Post-transplant corticosteroids were given to patient L9 as GVHD prophylaxis, in L6 as empiric treatment (14 days) for a toxic state (high fever, weight loss, diarrhea) primarily thought to have been related to her hematologic disease, and in the other patients as GVHD treatment. Patient L8 developed disseminated tuberculosis 14 months prior to the transplant, which resolved with 9 Isoniazid + rifampicin + pyrazinamide + ciprofloxacin. CMV = cytomegalovirus; CNS = central nervous system; Conditioning = ATG: antithymocyte globulin; BEAM (BCNU, etoposide, Ara-C, melphalan); CBV (cyclophosphamide, BCNU, etoposide); CCT (cyclophosphamide, thiotepa, carboplatin); TBI + CF (total body irradiation, cyclophosphamide); Day tbc = post-transplant day of tuberculosis presentation; GVHD (graft-versus-host disease): acute grade/chronic (ext: extensive) before tuberculosis presentation; Mng = meningeal; PL = pleura; NE = not evaluable; RI = respiratory insufficient; UD = underlying disease; AML: acute myelogenous leukemia; ALL: acute lymphoblastic leukemia; BC: breast cancer; HD: Hodgkin's disease; MM: multiple myeloma; NHL: non-Hodgkin's lymphoma.
months of treatment followed thereafter by isoniazid prophylaxis. All allogeneic patients, except cases L6, L8 and L9, suffered GVHD (acute and/or chronic) prior to the development of tuberculosis. Case L6 was severely immunosuppressed after relapsing from a second allogeneic transplant.
Characteristics, diagnosis, treatment and outcome of tuberculosis after SCT (Table 2)
The median day for tuberculosis presentation after transplant was 324 (range, 11-3337), without significant differences between allogeneic and autologous patients. Four patients had tuberculosis before day +100 post-transplant, and two of them died due to the infection. All patients had symptoms related to tuberculosis, that included fever (n = 15), cough (n = 13), constitutional syndrome (n = 4), dyspnea (n = 4), pleuritic chest pain (n = 1), knee pain (n = 1), oral pain (n = 1), and symptoms of dysfunction of the central nervous system including seizures (n = 2). The
Bone Marrow Transplantation median time from onset of symptoms to diagnosis was 30 days (range, 4-210), with no differences between allogeneic and autologous recipients. In two patients (L5 and L8) the diagnosis was made after death, although in one case (L8) it was suspected while the patient was alive and treated with an empirical tuberculostatic drug combination. The lungs were the most frequent site of disease, accounting for 80% of the cases. Two out of 16 patients with pulmonary tuberculosis had a normal chest X-ray (L2, L10). The other 14 patients had lung infiltrates, in five cases with multiple and bilateral lesions. One patient (L4) had a clinical picture resembling adult respiratory distress syndrome. In two patients (L8, L11) the diagnosis could only be made by studying tissue samples, as other less aggressive maneuvers (CSF, BAL and sputum) gave negative results. Nineteen patients received antituberculosis treatment with a median of three drugs (range, [3] [4] [5] [6] , and for a median of 6 months (range, 0.1-18) ( Table 1) . Seventeen patients received у3 months of antituberculosis treatment and all were cured without tuberculosis relapse thereafter. In four patients (L2, L3, L11, L12) cyclosporine was administered simultaneously with rifampicin, and in three of them (L2, L3, L11) cyclosporine levels decreased dramatically. In two patients (L2, L3) the decrease in the cyclosporine level was associated with an aggravation of chronic GVHD, both dying of lung GVHD long after the infection. Toxicity associated with the use of the antituberculosis treatment was reported in three patients (L2, L7, A1), all described as hepatotoxicity.
Eleven patients (55%) died during follow-up, three autologous and eight allogeneic recipients. Tuberculosis was the cause of death in three (L4, L5, L8). Mortality from tuberculosis was 25% in allogeneic patients and 0% in autologous. Two patients (L4, L5) died due to acute respiratory insufficiency (in one case tuberculosis was associated with cytomegalovirus), and one patient died due to a progressive neurologic deterioration (L8). Patient L5 received no antituberculosis therapy. Patient L4 started antituberculosis treatment late in his course (50 days after the beginning of symptoms) when the respiratory insufficiency was very severe, requiring mechanical ventilation. The third patient (L8) developed central nervous tuberculosis in spite of receiving isoniazid prophylaxis prior to the transplant, and died in spite of a four-drug regimen started only 4 days after the symptoms began.
Frequency and incidence of tuberculosis after SCT
The number of patients exposed ϫ year Ϫ1 was 19 900.116 for the entire group, 11 256.591 for autologous patients and 8849.091 for allogeneic patients. Using these numbers of exposed patients, the estimated incidence of tuberculosis in cases/10 5 patients/year (95% CI) after SCT was 101 (56.5-145) for the whole transplant group, 71.1 (21.8-120) for the autologous subgroup, and 135.6 (58.9-212) for allogeneic patients ( Table 2 ). The incidence for the whole group and for the allogeneic patients, but not for the autologous patients, was significantly higher than in the general population (38 cases/10 5 inhabitants/year) ( Table 2 ). There was no statistically significant difference in tuberculosis incidence between autologous and allogeneic patients. The relative risk (RR) of tuberculosis in SCT patients compared with the general population was 2.21 (95% CI, 1.58-3.08) in the entire group, 2.95 (95% CI, 1.80-4.84) in the allogeneic subgroup, and 1.72 (95% CI, 0.915-3.23) for autologous patients (Table 2) .
Since the estimated incidence of tuberculosis in the transplant population is largely dependent on the model used for estimation of the population-time accrued we recalculated the estimated incidence using a lower survival (30%) and a much higher survival (70%) at 4 years, maintaining the mortality assumptions at day +100. Using 30% and 70% survival at 4 years the estimated incidence of tuberculosis in cases/10 5 patients/year (95% CI) after SCT was respectively, 117 (65.7-168) and 70.2 (39.5-101) for the whole transplant group, 80.2 (24.5-136) and 53.5 (16.4-90.5) for the autologous subgroup, and 159 (69.1-249) and 87.4 (38-137) for allogeneic patients.
Literature review of tuberculosis after SCT
In the literature we found 33 cases (two autologous, 31 allogeneic) of post-SCT tuberculosis (Table 3) .
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Tuberculosis in hematopoietic stem cell transplantation R de la Cámara et al 295 Table 3 Published cases of Tuberculosis after hematopoietic progenitor transplants 11 were considered allogeneic and seven were considered autologous. g The patients in Martino et al study 7 were eliminated for 'All cases' as they were included in the survey. h Data from 44 cases with specified day of presentation. Day tbc = day of clinical presentation of tuberculosis after transplant; Localization = Pulm (pulmonary), Extrapulm (extrapulmonary), Diss (disseminated), Mng: meningeal; NES = not estimated; NR = not reported. these, only 21 cases had a complete report. 2, 3, [7] [8] [9] [10] [11] Of the allogeneic patients, two received the graft from a matched unrelated donor, 11 one from a haploidentical donor 13 and the rest from an identical sibling. Three patients (two allogeneic and one autologous) received a T cell-depleted graft. 5, 7 The median day for tuberculosis presentation was 150 (range, 23-2190). The lungs were the most frequent site of diseases (81.5%). The frequency of post-transplant tuberculosis was 0.49% (0.048% in autologous, 0.71% in allogeneic patients). Four out of 25 allogeneic patients, in whom the evolution of tuberculosis was reported, died due to the infection. Another five allogeneic patients died from other complications while having active tuberculosis, 10 to 192 days (median 47) after the beginning of symptoms. Thus, 37.5% of allogeneic patients died due to tuberculosis or with active tuberculosis.
Added to our cases there were 49 cases of post-transplant tuberculosis (40 allogeneic, nine autologous) in 13 917 patients (Table 3 ). This represents a frequency of 0.352% (0.129% in autologous, and 0.574% in allogeneic). The median day for tuberculosis presentation was 172 (range, 11-3337), in 44 cases in which the day of presentation was reported. Mortality rate from tuberculosis was 19.4% in allogeneic patients and 0% in autologous. Thirty-three per Bone Marrow Transplantation cent of the 36 allogeneic patients died due to tuberculosis or with active tuberculosis.
Discussion
In a national survey of tuberculosis after hematopoietic stem cell transplant (SCT), 20 confirmed cases were found (eight in autologous and 12 in allogeneic transplants) among 8013 patients, representing the largest series of tuberculosis in SCT published to date. In the literature we found 33 cases (two after autologous and 31 after allogeneic transplant) of post-SCT tuberculosis (Table 3) . [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Combined with our cases there were 49 post-transplant tuberculosis in 13917 patients (Table 3 ). This frequency is 10 times lower than the mean incidence of tuberculosis after solid organ transplant (3.7%).
14 If we compare the frequencies found in our series with the national incidence of tuberculosis (38/10 5 /year), the conclusion would be that SCT patients have a tuberculosis risk 6.5 times higher than the general population (four times for autologous, and 11 times for allogeneic patients). However, if we compare the estimated incidence for transplant patients instead of the relative frequency, a different picture emerges: the inci-dence in allogeneic transplants (RR 2.95), but not in autologous, was significantly higher compared with the incidence in the general population (Table 2) . Since the estimated incidence of tuberculosis in the transplant population is largely dependent on the model used for estimation of the population-time accrued we recalculated the incidence using a lower survival (30%) and a much higher survival (70%) at 4 years instead of the original 40%. Using these different estimations, the conclusions about tuberculosis incidence compared with the general population (higher incidence for allogeneic but not for autologous patients) did not change compared with the initial assumptions.
Only two studies 9,10 have compared the frequency of tuberculosis in SCT patients with that of the general population. Both concluded that the incidence of tuberculosis after SCT was higher (10-40 times) than in the general population. However, these studies did not compare the annual post-transplant tuberculosis incidence with the annual incidence of tuberculosis in the general population, but instead the relative frequency of tuberculosis in SCT with the annual incidence in the general population. The direct translation of relative frequency (number of cases of tuberculosis observed among the total number of transplant patients during a period of several years) into annual incidence is a statistical flaw that leads to an overestimation of tuberculosis incidence in the transplant population, probably by a factor of 5-10 times or more. We found that this direct translation of relative frequency of tuberculosis into annual incidence has also been made in all the major series of tuberculosis in solid organ transplants. 14, [26] [27] [28] In the published series of tuberculosis after transplantation, the number of cases observed is divided by the total number of transplant patients over a period of several years, without taking into account the period of time (that is the amount of population-time accrued). As a consequence, the denominator of the equation decreases and the resulting incidence is overestimated. This overestimation increases as the number of years of the study period and the survival of the transplant population increase.
A high incidence of tuberculosis might be expected in SCT patients, mainly in allogeneic recipients, due to the various and severe immunodeficiencies that affect these patients, but we found that its incidence was only moderately higher than in the general population: approximately twice. This is surprising as Spain has a high prevalence of infection (25-56%) 15, 16 and consequently a higher reactivation number was expected. Tuberculosis is less frequent in SCT than in other groups of patients with immunodeficiencies, such as solid organ transplant and AIDS patients. The reasons for this fact are not evident. One of the reasons could be type of immunosuppression. In SCT patients, immunosuppression, although profound is transient, while in AIDS and solid-organ transplants it is lifelong and can also be severe. The frequent and prolonged use of several antimicrobials which are active against Mycobacterium tuberculosis (particularly ciprofloxacin and aminoglucosides) during the pancytopenic phase of the transplant in SCT may also act as tuberculosis chemoprophylaxis. In fact, in one center ciprofloxacin was used as antituberculosis prophylaxis.
11
Tuberculosis post-SCT was a late infection (172-324 days), most frequently limited to the lungs (80%) and less frequently extrapulmonary or disseminated (Table 3 ). All SCT patients with tuberculosis were symptomatic, fever and cough being the most frequent symptoms. In contrast, in solid organ transplantation up to 10% of the patients with tuberculosis have been reported as being asymptomatic. 14 One patient in the present series had a clinical picture resembling an adult respiratory distress syndrome, a clinical picture previously reported as a frequent presentation in solid organ transplant recipients with tuberculosis.
14 Two out of our 16 patients with pulmonary tuberculosis had a normal chest X-ray. A similar frequency of this phenomenon has been described in HIV-infected patients. 29 In our series, autologous patients had several significant differences compared with allogeneic patients (Table 2) . GVHD, corticosteroid administration and TBI appear to be associated with tuberculosis in allogeneic patients. TBI, GVHD and allogeneic transplant have been described previously as risk factors for tuberculosis in SCT. 11 No obvious factors were associated with tuberculosis in autologous transplants. T cell depletion has been considered a risk factor for posttransplant tuberculosis. 7 Combining our series with the published cases we only found three patients out of 30 with T cell-depleted grafts and post-transplant tuberculosis. Thus, there are few data to support the hypothesis that T cell depletion increases the risk of post-transplant tuberculosis.
In allogeneic patients, tuberculosis is associated with a high mortality: 25% in our series and 16% in the literature reviewed. These data agree with the tuberculosis mortality rate in solid organ transplants (15-20%).
14 One third of the allogeneic SCT patients died due to tuberculosis or with active tuberculosis, usually within 2 months of presentation. In contrast, in autologous patients there were no deaths due to tuberculosis or with active tuberculosis. Summing up our series and the published cases, there were 12 allogeneic patients who died of tuberculosis or with active tuberculosis. Five of these 12 patients received no antituberculosis treatment, four received р1 month of treatment and in three cases no treatment information was available. Moreover, in allogeneic patients there was a median delay of 46 days from onset of symptoms to tuberculosis diagnosis. These data indicate that tuberculosis is usually not considered in the differential diagnosis with SCT patients. Factors that can decrease the physician's suspicion include steroid therapy (which can mask the symptoms) and immunosuppression, which can result in the coexistence of more than one pathogen. 3 This was the case in three out of 35 patients with lung tuberculosis: two had cytomegalovirus (patient L5 and Ref. 2) and one aspergillus. 3 Due to the high mortality associated with this infection, a higher index of suspicion is necessary in order to prompt appropriate diagnostic studies and start antituberculosis treatment as early as possible.
Patients were treated with a median of three antituberculosis drugs (range, [3] [4] [5] [6] , for a median of 6 months (range, 0.1-18). Interaction with cyclosporine was quite frequent in patients receiving concomitant rifampicin treatment resulting in aggravation of GVHD. This interaction between cyclosporine and rifampicin has been described in solid organ transplants as a serious event, being one of the most significant risk factors for mortality.
14 Rifampicin decreases cyclosporine levels by inducing hepatic metabolism of the drug and decreasing bioavailability of cyclosporine, 30 making maintenance of therapeutic cyclosporine levels very difficult. Thus, as has been recommended in solid organ transplants, 14 it could be better to avoid use of rifampicin in SCT patients receiving cyclosporine. Possible alternatives to rifampicin include the use of other rifamycins that produce less induction of the hepatic cytochrome P450, such as rifabutin, or the use of rifamycin-free regimens. These strategies have been proposed for HIVinfected individuals who take protease inhibitors or nonnucleoside reverse transcriptase inhibitors. 31, 32 Rifabutin has shown efficacy similar to rifampicin in randomized trials. [33] [34] [35] No study has been done with these alternative regimens in SCT patients. Therefore, due to the high mortality of tuberculosis in allogeneic SCT and the pivotal role that rifamycins have in tuberculosis treatment (rifampicin in particular), the decision to use or not to use rifampicin in SCT allogeneic patients is a difficult and unresolved problem. If rifampicin is to be administered, the cyclosporine dose should be increased three to five times, the frequency of administration of cyclosporine has to be increased to three times daily and serum levels should be monitored closely. 36 Need for antituberculosis prophylaxis in solid organ transplants and in SCT is controversial. The administration of isoniazid prophylaxis in SCT is complex, particularly in allogeneic transplants where GVHD frequently produces abnormalities in hepatic function that could be difficult to differentiate from isoniazid hepatotoxicity. The toxicity and efficacy of this prophylaxis have not been studied in SCT. In allogeneic patients tuberculosis incidence is higher than in the general population and is associated with a very high mortality. Thus, it would be reasonable to employ prophylaxis in a selected subgroup of allogeneic patients. The PPD test has not been studied systematically in SCT patients, but probably has a similar high rate of anergic responses as in other transplants (up to 85%). 37 In HIV-infected patients with anergy, isoniazid chemoprophylaxis does not reduce the incidence of tuberculosis compared with placebo. 38, 39 In the only published randomized study primary isoniazid prophylaxis was not superior compared to placebo in preventing post-transplant tuberculosis. 40 In autologous SCT, where the risk of tuberculosis is low (similar to the general population), treatment seems effective and no deaths have been reported, there seems to be little justification for routine prophylaxis even in PPD-positive patients. Nonetheless, the CDC recommended the use of the tuberculin test in all SCT patients. 41 In conclusion, tuberculosis is an infrequent infection after SCT even in countries like Spain with a high prevalence of tuberculosis infection. Compared with the general population, tuberculosis is more frequent after allogeneic SCT but probably not after autologous transplant. Nonetheless, it is a serious infection after allogeneic SCT and is associated with high mortality. It can also complicate posttransplant management as antituberculosis drugs frequently decrease serum levels of cyclosporine causing an aggravation of GVHD. Finally, we found that the published literature on tuberculosis after solid organ and hematopoietic
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